Loss of Response of Adalimumab Biosimilar vs Adalimumab Original, in Inflammatory Bowel Disease. (ADA-SWITCH)
Loss of Response of Adalimumab Biosimilar Compared With the Loss of Response of Adalimumab Original: Controlled, Randomized, Non-inferiority Open Study. ADA-SWITCH Study
Sponsor: Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
Terminated
Sponsor cancellation
Other terminated trials from Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
- Autoimmune Diseases · Phase PHASE1/PHASE2 · Feb 2026
- Assessment Evaluation · Phase NA · Jul 2025
- Idiopathic Pulmonary Fibrosis · Phase PHASE3 · Nov 2015
- Infection in Solid Organ Transplant Recipients · Phase PHASE3 · Feb 2014
See all terminations from Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
A PHASE4 clinical study on Crohn Disease and Ulcerative Colitis, this trial is terminated or withdrawn. The trial is conducted by Fundación Pública Andaluza para la gestión de la Investigación en Sevilla and has accumulated 6 data snapshots since 2019. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE4
-
Feb 2021 — Jul 2024 [monthly]
Terminated PHASE4
Status: Not Yet Recruiting → Terminated
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE4
▶ Show 1 earlier version
-
Nov 2019 — Jan 2021 [monthly]
Not Yet Recruiting PHASE4
First recorded
Oct 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Fundación Pública Andaluza para la gestión de la Investigación en Sevilla
For direct contact, visit the study record on ClinicalTrials.gov .